Non-interventional Management of Asymptomatic Diminutive Choledocholithiasis Versus Endoscopic Extraction in Consecutive Patients.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2023
Historique:
received: 17 03 2023
accepted: 28 07 2023
medline: 10 11 2023
pubmed: 28 10 2023
entrez: 27 10 2023
Statut: ppublish

Résumé

Current guidelines recommend treating choledocholithiasis, regardless of symptoms or stone size, with endoscopic retrograde cholangiopancreatography (ERCP). However, asymptomatic choledocholithiasis, discovered incidentally on imaging, may carry a higher risk of ERCP-related adverse events, and some asymptomatic and diminutive stones may not cause biliary adverse events during extended follow-up. Therefore, we aimed to clarify the best treatment strategies for asymptomatic choledocholithiasis based on stone size. We retrospectively identified patients with incidental imaging-found asymptomatic diminutive (≤ 4 mm) or non-diminutive (> 4 mm) choledocholithiasis and divided them into two groups: those who did not undergo ERCP and were treated when complications arose (on-demand group) and those who underwent ERCP before being symptomatic (intervention group). Adverse events were defined as any biliary or pancreatic complication related to ERCP or arising during observation or after intervention. The primary outcome was the adjusted overall adverse event-free survival using the propensity score-based matching weights method comparing the two groups of stone size. Among 148 patients identified (median follow-up period, 969 days), 68 had diminutive stones and 80 had non-diminutive stones. Of the 68 patients with diminutive stones, 51 were in the on-demand group and 17 in the intervention group. The overall adjusted adverse event-free survival was significantly higher in the on-demand group for diminutive stones (97.4% and 70.1%, respectively, at 3 years; p = 0.01). Patients with incidental imaging-detected asymptomatic diminutive choledocholithiasis may benefit from clinical observation, pursuing ERCP when symptoms develop.

Sections du résumé

BACKGROUND
Current guidelines recommend treating choledocholithiasis, regardless of symptoms or stone size, with endoscopic retrograde cholangiopancreatography (ERCP). However, asymptomatic choledocholithiasis, discovered incidentally on imaging, may carry a higher risk of ERCP-related adverse events, and some asymptomatic and diminutive stones may not cause biliary adverse events during extended follow-up. Therefore, we aimed to clarify the best treatment strategies for asymptomatic choledocholithiasis based on stone size.
METHODS
We retrospectively identified patients with incidental imaging-found asymptomatic diminutive (≤ 4 mm) or non-diminutive (> 4 mm) choledocholithiasis and divided them into two groups: those who did not undergo ERCP and were treated when complications arose (on-demand group) and those who underwent ERCP before being symptomatic (intervention group). Adverse events were defined as any biliary or pancreatic complication related to ERCP or arising during observation or after intervention. The primary outcome was the adjusted overall adverse event-free survival using the propensity score-based matching weights method comparing the two groups of stone size.
RESULTS
Among 148 patients identified (median follow-up period, 969 days), 68 had diminutive stones and 80 had non-diminutive stones. Of the 68 patients with diminutive stones, 51 were in the on-demand group and 17 in the intervention group. The overall adjusted adverse event-free survival was significantly higher in the on-demand group for diminutive stones (97.4% and 70.1%, respectively, at 3 years; p = 0.01).
DISCUSSION
Patients with incidental imaging-detected asymptomatic diminutive choledocholithiasis may benefit from clinical observation, pursuing ERCP when symptoms develop.

Identifiants

pubmed: 37891439
doi: 10.1007/s10620-023-08137-3
pii: 10.1007/s10620-023-08137-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4456-4465

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117:632–639.
doi: 10.1016/S0016-5085(99)70456-7 pubmed: 10464139
Tazuma S. Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best Pract Res Clin Gastroenterol. 2006;20:1075–1083.
doi: 10.1016/j.bpg.2006.05.009 pubmed: 17127189
Manes G, Paspatis G, Aabakken L et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51:472–491.
doi: 10.1055/a-0862-0346 pubmed: 30943551
ASGE Standards of Practice Committee, Maple JT, Ikenberry SO et al. The role of endoscopy in the management of choledocholithiasis. Gastrointest Endosc. 2011;74:731–744.
doi: 10.1016/j.gie.2011.04.012
Tazuma S, Unno M, Igarashi Y et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300.
doi: 10.1007/s00535-016-1289-7 pubmed: 27942871
Frossard JL, Hadengue A, Amouyal G et al. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. Gastrointest Endosc. 2000;51:175–179.
doi: 10.1016/S0016-5107(00)70414-7 pubmed: 10650260
Hakuta R, Hamada T, Nakai Y et al. Natural history of asymptomatic bile duct stones and association of endoscopic treatment with clinical outcomes. J Gastroenterol. 2020;55:78–85.
doi: 10.1007/s00535-019-01612-7 pubmed: 31473828
Kim SB, Kim KH, Kim TN. Comparison of outcomes and complications of endoscopic common bile duct stone removal between asymptomatic and symptomatic patients. Dig Dis Sci. 2016;61:1172–1177.
doi: 10.1007/s10620-015-3965-5 pubmed: 26589817
Saito H, Kakuma T, Kadono Y et al. Increased risk and severity of ERCP-related complications associated with asymptomatic common bile duct stones. Endosc Int Open. 2017;05:E809–E817.
doi: 10.1055/s-0043-107615
Testoni PA. No treatment for asymptomatic common bile ducts stones? Endosc Int Open. 2017;5:E1151–E1152.
doi: 10.1055/s-0043-107778 pubmed: 29124125 pmcid: 5677464
Saito H, Koga T, Sakaguchi M et al. Post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with asymptomatic common bile duct stones. J Gastroenterol Hepatol. 2019;34:1153–1159.
doi: 10.1111/jgh.14604 pubmed: 30650203
Xu X-D, Qian J-Q, Dai J-J, Sun Z-X. Endoscopic treatment for choledocholithiasis in asymptomatic patients. J Gastroenterol Hepatol. 2020;35:165–169.
doi: 10.1111/jgh.14790 pubmed: 31334888
Kadokura M, Takenaka Y, Yoda H et al. Asymptomatic common bile duct stones are associated with increased risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. JMA J. 2021;4:141–147.
doi: 10.31662/jmaj.2020-0123 pubmed: 33997448 pmcid: 8118962
Saito H, Kadono Y, Shono T et al. Endoscopic retrograde cholangiopancreatography-related complications for bile duct stones in asymptomatic and symptomatic patients. JGH Open. 2021;5:1382–1390.
doi: 10.1002/jgh3.12685 pubmed: 34950782 pmcid: 8674545
Möller M, Gustafsson U, Rasmussen F, Persson G, Thorell A. Natural course vs interventions to clear common bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks). JAMA Surg. 2014;149:1008–1013.
doi: 10.1001/jamasurg.2014.249 pubmed: 25133326
Kiriyama S, Kozaka K, Takada T et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepato-Biliary-Pancreat Sci. 2018;25:17–30.
doi: 10.1002/jhbp.512
Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.
doi: 10.1136/gutjnl-2012-302779 pubmed: 23100216
Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383–393.
doi: 10.1016/S0016-5107(91)70740-2 pubmed: 2070995
Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71:446–454.
doi: 10.1016/j.gie.2009.10.027 pubmed: 20189503
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679.
doi: 10.1002/sim.6607 pubmed: 26238958 pmcid: 4626409
Tanoue K, Fukunaga S, Nagami Y et al. Long-term outcome of endoscopic submucosal dissection for early gastric cancer in patients with severe comorbidities: a comparative propensity score analysis. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2019;22:558–566.
Kim S, Kim DH, Park S-Y et al. Association between Charlson comorbidity index and complications of endoscopic resection of gastric neoplasms in elderly patients. BMC Gastroenterol. 2020;20:213.
doi: 10.1186/s12876-020-01360-6 pubmed: 32646468 pmcid: 7346434
Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013;9:215–234.
doi: 10.1515/ijb-2012-0030 pubmed: 23902694
Caddy GR, Kirby J, Kirk SJ et al. Natural history of asymptomatic bile duct stones at time of cholecystectomy. Ulster Med J. 2005;74:108–112.
pubmed: 16235763 pmcid: 2475382
Collins C, Maguire D, Ireland A, Fitzgerald E, O’Sullivan GC. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg. 2004;239:28–33.
doi: 10.1097/01.sla.0000103069.00170.9c pubmed: 14685097 pmcid: 1356189
Hauer-Jensen M, Karesen R, Nygaard K et al. Prospective randomized study of routine intraoperative cholangiography during open cholecystectomy: long-term follow-up and multivariate analysis of predictors of choledocholithiasis. Surgery. 1993;113:318–323.
pubmed: 8441966
Khan OA, Balaji S, Branagan G, Bennett DH, Davies N. Randomized clinical trial of routine on-table cholangiography during laparoscopic cholecystectomy. Br J Surg. 2011;98:362–367.
doi: 10.1002/bjs.7356 pubmed: 21254008
Kochar B, Akshintala VS, Afghani E et al. Incidence, severity, and mortality of post-ERCP pancreatitis: A systematic review by using randomized, controlled trials. Gastrointest Endosc. 2015;81:143-149.e9.
doi: 10.1016/j.gie.2014.06.045 pubmed: 25088919
Sultan S, Baillie J. Recurrent bile duct stones after endoscopic sphincterotomy. Gut. 2004;53:1725–1727.
doi: 10.1136/gut.2004.046185 pubmed: 15542503 pmcid: 1774339
Xiao L, Geng C, Li X, Li Y, Wang C. Comparable safety of ERCP in symptomatic and asymptomatic patients with common bile duct stones: a propensity-matched analysis. Scand J Gastroenterol. 2021;56:111–117.
doi: 10.1080/00365521.2020.1853222 pubmed: 33295209
Loperfido S, Angelini G, Benedetti G et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1–10.
doi: 10.1016/S0016-5107(98)70121-X pubmed: 9684657
Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434.
doi: 10.1067/mge.2001.117550 pubmed: 11577302
Park BK, Seo JH, Jeon HH et al. A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea. J Gastroenterol. 2018;53:670–678.
doi: 10.1007/s00535-017-1419-x pubmed: 29192348
Kawaji Y, Isayama H, Nakai Y et al. Multiple recurrences after endoscopic removal of common bile duct stones: A retrospective analysis of 976 cases. J Gastroenterol Hepatol. 2019;34:1460–1466.
doi: 10.1111/jgh.14630 pubmed: 30761603
Takimoto Y, Irisawa A, Hoshi K et al. The impact of endoscopic sphincterotomy incision size on common bile duct stone recurrence: A propensity score matching analysis. J Hepato-Biliary-Pancreat Sci. 2022;29:1274–1282.
doi: 10.1002/jhbp.1083

Auteurs

Atsuto Kayashima (A)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Masayasu Horibe (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Eisuke Iwasaki (E)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. iwaiwa2007@gmail.com.

Fateh Bazerbachi (F)

CentraCare, Interventional Endoscopy Program, St. Cloud Hospital, St. Cloud, MN, USA.

Haruka Okada (H)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yuki Nakajima (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yosuke Mizukami (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yujiro Machida (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Shintaro Kawasaki (S)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Minoru Kitago (M)

Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.

Takanori Kanai (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH